Brind.

Indian Pharma Firm Files ANDA for Sitagliptin Tablets in US Market

2 reports, 2 independent Updated Mon 00:00
No new developments lately Reached 2 outlets in its first 24 hours
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Morepen Laboratories Limited submitted its first Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration for Sitagliptin Tablets USP in 25 mg, 50 mg, and 100 mg strengths. This filing marks the company's entry into finished dosage regulatory submissions for the U.S. market. Morepen estimates a 24 to 36-month timeline from submission to potential approval and commercial supply.

From equitybulls.com, thehindubusinessline.com

Why it matters

Some supportBrind's analysis of the reports

Sitagliptin is a Type 2 diabetes treatment, and the branded version, Januvia, marketed by Merck, generated global sales of approximately $1.604 billion in 2025. The relevant U.S. phosphate salt patent is scheduled to expire in November 2026, making the generic filing a significant market entry.

From thehindubusinessline.com

Who's involved

  • MerckMerck markets the branded version of Sitagliptin, Januvia.
  • Sanjay SuriSanjay Suri is the Managing Director of the company that submitted the ANDA.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • MerckSpeculative

    Merck could face a long-term threat to revenue as generic competitors enter the market following patent expiration.

How this reaches others

Each traced step by step, with the reporting behind it

How it developed

Newest first. Tap a step to see who reported it.
  1. First ANDA submitted for Sitagliptin tablets, targeting future development in regulated markets.1 source
  2. ANDA submission for Sitagliptin resulted in market entry of the branded version Januvia, according to expert commentary.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped